Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 324-328

  Pabba, Chittari ^a   Gregg, Brian T ^a   Kitchen, Douglas B ^a   Chen, Zhen Jia ^a   Judkins, Angela ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

Anticancer agents; Cell cycle arrest; HDAC; HDAC inhibitors; Histone deacetylase; Hydroxamic acids; Molecular modeling

Indexed keywords

ARYLETHER HYDROXAMIC ACID; CARBON; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; SULFONE HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; SUBSTITUTION REACTION;

BINDING SITES; CATALYTIC DOMAIN; DRUG DESIGN; ETHERS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 78650513499     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.006     Document Type: Article

References (48)

1. M. Paris, M. Porcelloni, M. Binaschi, and D. Fattori J. Med. Chem. 51 2008 1505
2. S. Cang, Y. Ma, and D. Liu J. Hematol. Oncol. 22 2009 9
3. F. Manzo, F.P. Tambaro, A. Mai, and L. Altucci Expert Opin. Ther. Patents 19 2009 761
4. U. Tibes Prog. Med. Chem. 46 2008 205
5. G.A. Villar, and M. Esteller Int. J. Cancer 112 2004 171
6. J.-H. Park, Y. Jung, Y.Y. Kim, S.G. Kim, H.-S. Jong, J.W. Lee, D.-K. Kim, J.-S. Lee, N.K. Kim, T.-Y. Kim, and Y.-J. Bang Clin. Cancer Res. 10 2004 5721
7. A. Xie, C. Liao, Z. Li, Z. Ning, W. Hu, X. Lu, L. Shi, and J. Zhou J. Curr. Med. Chem. Anti-Cancer Agents 4 2004 273
8. P.A. Marks, T. Miller, and V.M. Richon Curr. Opin. Pharmacol. 3 2003 344
9. G. Bouchain, and D. Delrome Curr. Med. Chem. 10 2003 2359
10. C.M. Crews, and J.B. Shotwell Prog. Cell Cycle Res. 5 2003 125
11. W.K. Kelly, O.A. O'Connor, and P.A. Marks Expert Opin. Invest. Drugs 11 2002 1695
12. A. Grossmann, and U.H. Weidle Anticancer Res. 20 2000 1471
13. P. Bertrand Eur. J. Med. Chem. 45 2010 2095
14. P. ten Holte, K. Van Emelen, P.C. Janicot, J.S. de Bono, and J. Arts Top. Med. Chem. 1 2007 293
15. C.M. Marson, T. Mahadevan, J. Dines, S. Sengmany, J.M. Morell, J.P. Alao, P.S. Joel, D.M. Vigushin, and R.C. Coombes Bioorg. Med. Chem. 17 2007 136
16. R. Varshochi, F. Halim, A. Sunters, J.P. Alao, P.A. Madureira, S.M. Hart, S. Ali, D.M. Vigushin, R.C. Coombes, and E.W. Lam J. Biol. Chem. 280 2005 3185
17. D.M. Vigushin, S. Ali, P.E. Pace, N. Mirsaidi, K. Ito, I. Adcock, and R.C. Coombes Clin. Cancer Res. 7 2001 971
18. I. Flemming, J. Iqbal, and E.-P. Krebs Tetrahedron 39 1983 841
19. K. Mori, and K. Koseki Tetrahedron 44 1988 6013
20. S. Hosokawa, T. Ogura, H. Togashi, and K. Tatsuta Tetrahedron Lett. 46 2005 333
21. A. Yurek-George, F. Habens, M. Brimmell, G. Packham, and A. Ganesan J. Am. Chem. Soc. 126 2004 1030
22. Y. Dai, Y. Guo, J. Guo, L.J. Pease, J. Li, P.A. Marcotte, K.B. Glaser, P. Tapang, D.H. Albert, P.L. Richardson, S.K. Davidsen, and M.R. Michaelides Bioorg. Med. Chem. Lett. 13 2003 1897
23. D.-K. Kim, Y.J. Lee, J.-S. Kim, J.-H. Ryu, J.-Y. Choi, J.W. Lee, G.-J. Im, T.-K. Kim, J.W. Seo, H.-J. Park, J. Yoo, J.-H. Park, T.-Y. Kim, and Y.-J. Bang J. Med. Chem. 46 2003 5745
24. A. Mai, S. Massa, R. Pezzi, D. Rotilli, P. Loidl, and G. Brosch J. Med. Chem. 46 2003 4826
25. S.W. Remiszewski, L.C. Sambucetti, K.W. Bair, J. Bontempo, D. Cesarz, N. Chandramouli, R. Chen, M. Cheung, S. Cornell-Kennon, K. Dean, G. Diamantidis, D. France, M.A. Green, K.L. Howell, R. Kashi, P. Kwon, P. Lassota, M.S. Martin, Y. Mou, L.B. Perez, S. Sharma, T. Smith, E. Sorensen, F. Taplin, N. Trogani, R. Versace, H. Walker, S. Weltchek-Engler, A. Wood, A. Wu, and P. Atadja J. Med. Chem. 46 2003 4609
26. G. Bouchain, S. Leit, S. Frechette, E.A. Khalil, R. Lavoie, O. Moradei, S.H. Woo, M. Fournel, P.T. Yan, A. Kalita, M.-C. Trachy-Bourget, C. Beaulieu, Z. Li, M.-F. Robert, A.R. MacLeod, J.M. Besterman, and D. Delorme J. Med. Chem. 46 2003 820
27. S.H. Woo, S. Frechette, E.A. Khalil, G. Bouchain, A. Vaisburg, N. Bernstein, O. Moradei, S. Leit, M. Allan, M. Fournel, M.-C. Trachy-Bourget, Z. Li, J.M. Besterman, and D. Delorme J. Med. Chem. 45 2002 2877
28. A. Mai, S. Massa, R. Ragno, M. Esposito, G. Sbardella, G. Nocca, R. Scatena, F. Jesacher, P. Loidl, and G. Brosch J. Med. Chem. 45 2002 1778
29. S.W. Remiszewski, L.C. Sambucetti, P. Atadja, K.W. Bair, W.D. Cornell, M.A. Green, K.L. Howell, M. Jung, P. Kwon, N. Trogani, and H. Walker J. Med. Chem. 45 2002 753
30. M. Fournel, M.-C.T. Bourget, P.T. Yan, A. Kalita, C. Bonfils, C. Beaulieu, S. Frecherte, S. Leit, E. Abu-Khalil, S.-H. Woo, D. Delorme, A.R. MacLeod, J.M. Besterman, and Z. Li Cancer Res. 63 2002 4325
31. G.J. Mudler, and J.H. Merman Environ. Health Perspect. 49 1983 5097
32. S. Vassiliou, A. Mucha, P. Cuniasse, D. Georgiadis, K. Lucet-Levannier, F. Beau, R. Kannan, G. Murphy, V. Knaeper, M.C. Rio, P. Basset, A. Yiotakis, and V. Dive J. Med. Chem. 42 1999 2610
33. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, P.A. Marks, R. Breslow, and N. Pavletich Nature 401 1999 188
34. SAHA was approved by FDA in 2006 as Vorinostat (Merck), P.A. Marks Oncogene 2007 1351 and Panobinostat (LBH-589) in Phase III (Novartis)
35. E. Vickerstaffe, B.H. Warrington, M. Ladlow, and S.V. Ley Org. Biomol. Chem. 1 2003 2419
36. S.M. Sternson, J.C. Wong, C.M. Grozinger, and S.L. Schreiber Org. Lett. 3 2003 4239 and Ref. 4
37. P.A. Clarke, R.L. Davie, and S. Peace Tetrahedron 61 2005 2335
38. 3H resin avoided tedious purification of final compounds.
39. P.C. Chen, V. Patil, W. Guerrant, P. Green, and A.K. Oyelere Bioorg. Med. Chem. 16 2008 4839
40. T.A. Miller, D.J. Witter, and S. Belvedere J. Med. Chem. 46 2003 5097
41. C. Salmi-Smail, A. Fabre, F. Dequiedt, A. Restouin, R. Castellano, S. Garbit, P. Rocje, X. Morelli, J.M. Brunel, and Y. Collette J. Med. Chem. 53 2010 3038
42. F. Oger, A. Lecorgne, E. Sala, V. Nardese, F. Demay, S. Chevance, D.C. Desravines, N. Aleksandrova, R. Le Guevel, S. Lorenzi, A.R. Beccari, P. Barath, D.J. Hart, A. Bondon, D. Carettoni, G. Simonnequx, and G. Salbert J. Med. Chem. 53 2010 1937
43. 3H]acetic acid) with ethyl acetate quantification by liquid scintillation counting. Each test compound was assayed in duplicate whilst positive control (trichostatin A) and negative control samples were assayed in triplicate. Further details are provided in reference: C.M. Marson, N. Serradji, A.S. Rioja, S.P. Gastaud, J.P. Alao, R.C. Coombes, and D.M. Vigushin Bioorg. Med. Chem. Lett. 14 2004 2477
44. M.C. Marson, P. Savy, A.P. Rioja, T. Mahadevan, C. Miko, A. Veerupalli, E. Nsubuga, A. Chahwan, and S.P. Joel J. Med. Chem. 49 2006 800
45. 16
46. Molecular Operating Environment (MOE), Chemical Computing Group, Inc., Montreal, ON.
47. D.P. Dowling, S.L. Gantt, S.G. Gattis, C.A. Fierke, and D.W. Christianson Biochemistry 47 2008 13554
48. bmin, version 9.7.110, Schrodinger, Inc.: NY, NY.